Aurora Cannabis Launches US$100 Million At-the-Market Equity Program to Fund Growth
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aurora Cannabis ( (TSE:ACB) ) has shared an update.
On February 4, 2026, Aurora Cannabis Inc. filed a prospectus supplement to launch a new at-the-market equity offering program that will allow the company to issue and sell up to US$100 million of common shares from treasury on the Nasdaq or other U.S. marketplaces. The shares may be sold from time to time at prevailing market prices, via at-the-market distributions or privately negotiated transactions, under a sales agreement with TD Securities (USA) LLC, with no sales to be made on Canadian exchanges; Aurora says it intends to deploy the proceeds for strategic, accretive uses, including expanding cultivation capacity and pursuing mergers and acquisitions, signaling an effort to fund growth initiatives and strengthen its competitive position in global medical cannabis markets.
The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$5.50 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.
Spark’s Take on TSE:ACB Stock
According to Spark, TipRanks’ AI Analyst, TSE:ACB is a Neutral.
Aurora Cannabis faces significant financial challenges, with ongoing losses and cash flow issues weighing heavily on its score. While recent earnings call highlights and strategic investments in international markets provide some optimism, the overall outlook remains cautious due to valuation concerns and technical indicators suggesting bearish momentum.
To see Spark’s full report on TSE:ACB stock, click here.
More about Aurora Cannabis
Aurora Cannabis Inc. is a Canadian-based global leader in medical cannabis, supplying both medical and consumer markets across Canada, Europe, Australia and New Zealand with a portfolio of brands including Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty’s and Whistler Cannabis Co. The company emphasizes a medical-first, high-margin strategy, operates GMP-certified production facilities in Canada and Germany, and also holds a controlling interest in Bevo Farms, a major North American supplier of propagated agricultural plants. Its shares trade on Nasdaq and the Toronto Stock Exchange under the symbol ACB.
Average Trading Volume: 556,396
Technical Sentiment Signal: Sell
Current Market Cap: C$305.1M
For a thorough assessment of ACB stock, go to TipRanks’ Stock Analysis page.
